The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss drugs during widespread shortages to halt production now that supplies are stabilizing.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its shortage list.